Diagnosis and management of interstitial lung disease
- PMID: 25505696
- PMCID: PMC4215823
- DOI: 10.1186/2213-0802-2-4
Diagnosis and management of interstitial lung disease
Abstract
The complex tasks of making a confident diagnosis of a specific form of interstitial lung disease (ILD) and formulating a patient-centered, personalized management plan in an attempt to achieve remission or stabilization of the disease process can pose formidable challenges to clinicians. When patients are evaluated for suspected ILD, an accurate diagnosis of the specific form of ILD that a patient has developed must be made to provide the patient with useful prognostic information and to formulate an appropriate management plan that can relieve symptoms and restore or significantly improve quality of life. A well-performed patient history and physical examination provides invaluable information that can be combined with appropriate laboratory testing, imaging, and, if needed, tissue biopsy to reach a confident ILD diagnosis, and high-resolution computed tomography (HRCT) of the thorax is usually a key component of the diagnostic evaluation. If treatment is indicated, many forms of ILD can respond significantly to immunosuppressive anti-inflammatory therapies. However, ILD accompanied by extensive fibrosis may be difficult to treat, and the identification of an effective pharmacologic therapy for idiopathic pulmonary fibrosis (IPF) has remained elusive despite the completion of many phase 3 clinical trials over the past decade. Nonetheless, patients with IPF or advanced forms of non-IPF ILD can benefit significantly from detection and treatment of various co-morbid conditions that are often found in patients (especially the elderly patient), and supportive care (oxygen therapy, pulmonary rehabilitation) can have a beneficial impact on quality of life and symptom palliation. Finally, lung transplantation is an option for patients with progressive, advanced disease that does not respond to other therapies, but only a relatively small subset of patients with end-stage ILD are able to meet wait listing requirements and eventually undergo successful lung transplantation.
Keywords: Diagnosis; Idiopathic pulmonary fibrosis; Interstitial lung disease; Therapeutics.
Figures
Similar articles
-
The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease: A prospective study.Chest. 1999 Nov;116(5):1168-74. doi: 10.1378/chest.116.5.1168. Chest. 1999. PMID: 10559072
-
Interstitial lung disease in the elderly: pathogenesis, diagnosis and management.Sarcoidosis Vasc Diffuse Lung Dis. 2011 Jul;28(1):3-17. Sarcoidosis Vasc Diffuse Lung Dis. 2011. PMID: 21796886 Review.
-
A cohort study of Danish patients with interstitial lung diseases: burden, severity, treatment and survival.Dan Med J. 2015 Apr;62(4):B5069. Dan Med J. 2015. PMID: 25872544 Review.
-
Management of interstitial lung disease in elderly patients.Curr Opin Pulm Med. 2012 Sep;18(5):483-92. doi: 10.1097/MCP.0b013e3283541337. Curr Opin Pulm Med. 2012. PMID: 22617808 Review.
-
Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.Lancet Respir Med. 2020 May;8(5):453-460. doi: 10.1016/S2213-2600(20)30036-9. Epub 2020 Mar 5. Lancet Respir Med. 2020. PMID: 32145830 Clinical Trial.
Cited by
-
The radiologist's role in detecting systemic anticancer therapy-related interstitial lung disease: an educational review.Insights Imaging. 2024 Aug 1;15(1):191. doi: 10.1186/s13244-024-01771-z. Insights Imaging. 2024. PMID: 39090512 Free PMC article. Review.
-
Comparison of Interstitial Lung Disease Between Antineutrophil Cytoplasmic Antibodies Positive and Negative Patients: A Retrospective Cohort Study.ACR Open Rheumatol. 2024 Aug;6(8):463-469. doi: 10.1002/acr2.11679. Epub 2024 May 11. ACR Open Rheumatol. 2024. PMID: 38733262 Free PMC article.
-
Safety profile of trastuzumab deruxtecan in advanced breast cancer: Expert opinion on adverse event management.Clin Transl Oncol. 2024 Jul;26(7):1539-1548. doi: 10.1007/s12094-024-03383-x. Epub 2024 Feb 9. Clin Transl Oncol. 2024. PMID: 38336982 Free PMC article. Review.
-
Analysis of 12 cases of antineoplastic agents-induced interstitial lung disease.Front Pharmacol. 2023 Aug 28;14:1218480. doi: 10.3389/fphar.2023.1218480. eCollection 2023. Front Pharmacol. 2023. PMID: 37701034 Free PMC article.
-
Diagnostic yield, safety and therapeutic consequences of myocardial biopsy in clinically suspected fulminant myocarditis unweanable from mechanical circulatory support.Ann Intensive Care. 2023 Aug 31;13(1):78. doi: 10.1186/s13613-023-01169-y. Ann Intensive Care. 2023. PMID: 37653258 Free PMC article.
References
-
- Meyer KC, Raghu G. Patient evaluation. In: Baughman RP, Du Bois RM, editors. Interstitial Lung Disease: A Practical Approach. Second. New York: Springer; 2011. pp. 3–16.
-
- Meyer KC. Interstitial lung disease in the elderly: pathogenesis, diagnosis and management. Sarcoidosis Vasc Diffuse Lung Dis. 2011;28:3–17. - PubMed
-
- Swigris JJ, Brown KK, Flaherty KR. The idiopathic interstitial pneumonias and connective tissue disease-associated interstitial lung disease. Curr Rheum Rev. 2010;6:91–98. doi: 10.2174/157339710791330731. - DOI
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
